IL157208A0 - 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical - Google Patents

4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical

Info

Publication number: IL157208A0
Authority: IL; Israel
Prior art keywords: indan; fluoro; benzamide; pharmaceutical; synthase
Prior art date: 2001-02-13

Application number

IL15720802A

Other languages

English (en)

Original Assignee

Aventis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-13

Filing date

2002-02-12

Publication date

2004-02-19

2002-02-12 Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh

2004-02-19 Publication of IL157208A0 publication Critical patent/IL157208A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Gynecology & Obstetrics (AREA)
Obesity (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL15720802A 2001-02-13 2002-02-12 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical IL157208A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP01102852		2001-02-13
PCT/EP2002/001443 WO2002064146A1 (en)	2001-02-13	2002-02-12	4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical

Publications (1)

Publication Number	Publication Date
IL157208A0 true IL157208A0 (en)	2004-02-19

Family

ID=8176423

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL15720802A IL157208A0 (en)	2001-02-13	2002-02-12	4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical
IL157208A IL157208A (en)	2001-02-13	2003-08-03	4-Fluoro-N-indene-2-ilbenzamide and its use in the manufacture of drugs

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL157208A IL157208A (en)	2001-02-13	2003-08-03	4-Fluoro-N-indene-2-ilbenzamide and its use in the manufacture of drugs

Country Status (33)

Country	Link
US (3)	US6617359B2 (xx)
EP (1)	EP1361882B1 (xx)
JP (1)	JP4317689B2 (xx)
KR (1)	KR101017531B1 (xx)
CN (1)	CN100553631C (xx)
AT (1)	ATE344669T1 (xx)
AU (1)	AU2002253009B2 (xx)
BG (1)	BG66065B1 (xx)
BR (1)	BR0207178A (xx)
CA (1)	CA2437966C (xx)
CY (1)	CY1106278T1 (xx)
CZ (1)	CZ20032154A3 (xx)
DE (1)	DE60215919T2 (xx)
DK (1)	DK1361882T3 (xx)
EE (1)	EE05302B1 (xx)
ES (1)	ES2274025T3 (xx)
HR (1)	HRP20030646A2 (xx)
HU (1)	HUP0302845A3 (xx)
IL (2)	IL157208A0 (xx)
MX (1)	MXPA03006841A (xx)
MY (1)	MY135778A (xx)
NO (1)	NO333522B1 (xx)
NZ (1)	NZ527469A (xx)
PE (1)	PE20020884A1 (xx)
PL (1)	PL363452A1 (xx)
PT (1)	PT1361882E (xx)
RS (1)	RS51645B (xx)
RU (1)	RU2308946C2 (xx)
SI (1)	SI1361882T1 (xx)
SK (1)	SK286513B6 (xx)
TW (1)	TWI241190B (xx)
WO (1)	WO2002064146A1 (xx)
ZA (1)	ZA200305412B (xx)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY136316A (en) *	2001-02-13	2008-09-30	Sanofi Aventis Deutschland	Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical.
TWI243164B (en) *	2001-02-13	2005-11-11	Aventis Pharma Gmbh	Acylated indanyl amines and their use as pharmaceuticals
TWI241190B (en) *	2001-02-13	2005-10-11	Aventis Pharma Gmbh	4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
EP1388342A1 (en) *	2002-08-07	2004-02-11	Aventis Pharma Deutschland GmbH	Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7186735B2 (en)	2002-08-07	2007-03-06	Sanofi-Aventis Deutschland Gmbh	Acylated arylcycloalkylamines and their use as pharmaceuticals
US7105513B2 (en) *	2002-08-07	2006-09-12	Sanofi-Avertis Deutschland Gmbh	Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
EP1388341A1 (en) *	2002-08-07	2004-02-11	Aventis Pharma Deutschland GmbH	Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US7338956B2 (en)	2002-08-07	2008-03-04	Sanofi-Aventis Deutschland Gmbh	Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
WO2004037779A1 (en)	2002-10-21	2004-05-06	Janssen Pharmaceutica, N.V.	Substituted tetralins and indanes and their use
WO2004047743A2 (en) *	2002-11-22	2004-06-10	Bristol-Myers Squibb Company	1-aryl-2-hydroxyethyl amides as potassium channel openers
US7132536B2 (en) *	2003-04-24	2006-11-07	Sanofi-Aventis Deutschland Gmbh	Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals
JP2007520440A (ja) *	2003-07-03	2007-07-26	イーライリリーアンドカンパニー	ムスカリン性受容体アゴニストとしてのインダン誘導体
WO2005018620A2 (en) *	2003-08-26	2005-03-03	Cell Center Cologne Gmbh	Use of nitric oxide synthase (nos) cofactor for the treatment of sexual dysfunction
US8309608B2 (en) *	2003-11-06	2012-11-13	Sanofi-Aventis Deutschland Gmbh	Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
EP1529525A1 (en) *	2003-11-06	2005-05-11	Aventis Pharma Deutschland GmbH	ENOS transcription enhancers for use in the cell therapy of ischemic heart diseases
AU2004291149C1 (en)	2003-11-17	2021-01-21	Biomarin Pharmaceutical Inc.	Methods and Compositions for the Treatment of Metabolic Disorders
AR048931A1 (es)	2004-04-21	2006-06-14	Janssen Pharmaceutica Nv	Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis
EP2436379A1 (en) *	2004-11-17	2012-04-04	BioMarin Pharmaceutical Inc.	Stable tablet formulation
WO2006055833A2 (en) *	2004-11-19	2006-05-26	Children's Hospital Medical Center	Gtpase inhibitors and use thereof for controlling platelet hyperactivity
US20060185492A1 (en)	2005-02-18	2006-08-24	Francois Chianese	Shoulder bushing for saw blades
EP1741709A1 (en)	2005-06-28	2007-01-10	Sanofi-Aventis Deutschland GmbH	Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
EP1741708A1 (en)	2005-06-28	2007-01-10	Sanofi-Aventis Deutschland GmbH	Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
US7795101B2 (en) *	2006-04-03	2010-09-14	United Microelectronics Corp.	Method of forming a MOS transistor
EP1905764A1 (en)	2006-09-30	2008-04-02	Sanofi-Aventis	Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals
EP1923062A1 (en)	2006-11-16	2008-05-21	sanofi-aventis	Imidazo[2,1-b]thiazoles and their use as pharmaceuticals
KR101349187B1 (ko) *	2006-12-05	2014-01-10	(주)아모레퍼시픽	지방대사 이상질환의 치료 및 예방용 약학 조성물
EP1939180A1 (en)	2006-12-20	2008-07-02	sanofi-aventis	Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1942104A1 (en)	2006-12-20	2008-07-09	sanofi-aventis	Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939181A1 (en)	2006-12-27	2008-07-02	sanofi-aventis	Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
EP1964840A1 (en)	2007-02-28	2008-09-03	sanofi-aventis	Imidazo[1,2-a]pyridines and their use as pharmaceuticals
EP1964841A1 (en)	2007-02-28	2008-09-03	sanofi-aventis	Imidazo[1,2-a]azine and their use as pharmaceuticals
US20160169868A9 (en) *	2007-05-24	2016-06-16	Calcimedica, Inc.	Calcium channel proteins and uses thereof
AU2008311053B2 (en) *	2007-10-09	2012-08-30	Novartis Ag	Pharmaceutical formulation of valsartan
RU2400825C1 (ru) *	2009-06-10	2010-09-27	Государственное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко Федерального агентства по здравоохранению и социальному развитию"	СПОСОБ ОДНОВРЕМЕННОЙ РЕГИСТРАЦИИ Na+-ЗАВИСИМЫХ ПОТОКОВ Ca2+ И ФУНКЦИОНАЛЬНОГО СОСТОЯНИЯ ЦЕЛОГО ИЗОЛИРОВАННОГО СЕРДЦА В ЭКСПЕРИМЕНТЕ
US20130178475A1 (en)	2010-03-17	2013-07-11	Ironwood Pharmaceuticals, Inc.	sGC STIMULATORS
DK2588465T3 (en)	2010-06-30	2017-05-01	Ironwood Pharmaceuticals Inc	SGC stimulators
RU2582679C2 (ru)	2010-11-09	2016-04-27	Айронвуд Фармасьютикалз, Инк.	СТИМУЛЯТОРЫ sGC
US9216178B2 (en)	2011-11-02	2015-12-22	Biomarin Pharmaceutical Inc.	Dry blend formulation of tetrahydrobiopterin
EP2797915B1 (en)	2011-12-27	2016-07-13	Ironwood Pharmaceuticals, Inc.	2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure
US9309235B2 (en)	2012-09-18	2016-04-12	Ironwood Pharmaceuticals, Inc.	SGC stimulators
CA2885645A1 (en)	2012-09-19	2014-03-27	Ironwood Pharmaceuticals, Inc.	Sgc stimulators
LT3660013T (lt)	2013-03-15	2022-04-11	Cyclerion Therapeutics, Inc.	Tgs stimuliatoriai
MX2016007522A (es)	2013-12-11	2017-12-15	Ironwood Pharmaceuticals Inc	Estimuladores de guanilato ciclasa soluble (sgc).
EP3094327A1 (en)	2014-01-13	2016-11-23	Ironwood Pharmaceuticals, Inc.	USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
US10028503B2 (en)	2014-06-18	2018-07-24	Children's Hospital Medical Center	Platelet storage methods and compositions for same
US10844064B2 (en)	2014-09-17	2020-11-24	Cyclerion Therapeutics, Inc.	sGC stimulators
US20170291889A1 (en)	2014-09-17	2017-10-12	Ironwood Pharmaceuticals, Inc.	Pyrazole derivatives as sgc stimulators
WO2016044445A2 (en)	2014-09-17	2016-03-24	Ironwood Pharmaceuticals, Inc.	sGC STIMULATORS
US10889577B2 (en)	2016-07-07	2021-01-12	Cyclerion Therapeutics, Inc.	Solid forms of an sGC stimulator
KR102513343B1 (ko)	2016-07-07	2023-03-22	사이클리온 테라퓨틱스, 인크.	sGC 자극제의 인 전구약물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5932765A (en) *	1997-05-23	1999-08-03	Merck Patent Gesellschaft Mit	Nitromethyl ketones, process for preparing them and compositions containing them
US6180597B1 (en)	1998-03-19	2001-01-30	Brigham And Women's Hospital, Inc.	Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
WO2000003746A2 (en)	1998-07-14	2000-01-27	The Brigham And Women's Hospital, Inc.	Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
AUPP891299A0 (en) *	1999-02-26	1999-03-25	Fujisawa Pharmaceutical Co., Ltd.	New 6-membered cyclic compounds
WO2001091752A1 (en) *	2000-05-30	2001-12-06	Merck & Co., Inc.	Melanocortin receptor agonists
TWI243164B (en)	2001-02-13	2005-11-11	Aventis Pharma Gmbh	Acylated indanyl amines and their use as pharmaceuticals
TWI241190B (en) *	2001-02-13	2005-10-11	Aventis Pharma Gmbh	4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
MY136316A (en)	2001-02-13	2008-09-30	Sanofi Aventis Deutschland	Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical.
PE20020856A1 (es)	2001-02-13	2002-11-11	Aventis Pharma Gmbh	1,2,3,4-tetrahidronaftil aminas aciladas
US7105513B2 (en)	2002-08-07	2006-09-12	Sanofi-Avertis Deutschland Gmbh	Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7338956B2 (en)	2002-08-07	2008-03-04	Sanofi-Aventis Deutschland Gmbh	Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US7186735B2 (en)	2002-08-07	2007-03-06	Sanofi-Aventis Deutschland Gmbh	Acylated arylcycloalkylamines and their use as pharmaceuticals
US8309608B2 (en)	2003-11-06	2012-11-13	Sanofi-Aventis Deutschland Gmbh	Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases

2002
- 2002-02-08 TW TW091102292A patent/TWI241190B/zh not_active IP Right Cessation
- 2002-02-11 MY MYPI20020481A patent/MY135778A/en unknown
- 2002-02-12 EE EEP200300368A patent/EE05302B1/xx not_active IP Right Cessation
- 2002-02-12 AU AU2002253009A patent/AU2002253009B2/en not_active Ceased
- 2002-02-12 CN CNB028048636A patent/CN100553631C/zh not_active Expired - Fee Related
- 2002-02-12 IL IL15720802A patent/IL157208A0/xx unknown
- 2002-02-12 PT PT02722066T patent/PT1361882E/pt unknown
- 2002-02-12 CA CA2437966A patent/CA2437966C/en not_active Expired - Fee Related
- 2002-02-12 NZ NZ527469A patent/NZ527469A/xx not_active IP Right Cessation
- 2002-02-12 RS YU61703A patent/RS51645B/sr unknown
- 2002-02-12 JP JP2002563939A patent/JP4317689B2/ja not_active Expired - Fee Related
- 2002-02-12 KR KR1020037010490A patent/KR101017531B1/ko not_active Expired - Fee Related
- 2002-02-12 SK SK1011-2003A patent/SK286513B6/sk not_active IP Right Cessation
- 2002-02-12 ES ES02722066T patent/ES2274025T3/es not_active Expired - Lifetime
- 2002-02-12 HR HR20030646A patent/HRP20030646A2/hr not_active Application Discontinuation
- 2002-02-12 BR BR0207178-9A patent/BR0207178A/pt not_active Application Discontinuation
- 2002-02-12 SI SI200230443T patent/SI1361882T1/sl unknown
- 2002-02-12 AT AT02722066T patent/ATE344669T1/de active
- 2002-02-12 CZ CZ20032154A patent/CZ20032154A3/cs unknown
- 2002-02-12 RU RU2003127750/15A patent/RU2308946C2/ru not_active IP Right Cessation
- 2002-02-12 DE DE60215919T patent/DE60215919T2/de not_active Expired - Lifetime
- 2002-02-12 EP EP02722066A patent/EP1361882B1/en not_active Expired - Lifetime
- 2002-02-12 PL PL02363452A patent/PL363452A1/xx not_active Application Discontinuation
- 2002-02-12 HU HU0302845A patent/HUP0302845A3/hu unknown
- 2002-02-12 DK DK02722066T patent/DK1361882T3/da active
- 2002-02-12 WO PCT/EP2002/001443 patent/WO2002064146A1/en not_active Ceased
- 2002-02-12 MX MXPA03006841A patent/MXPA03006841A/es active IP Right Grant
- 2002-02-13 US US10/073,330 patent/US6617359B2/en not_active Expired - Lifetime
- 2002-02-13 PE PE2002000123A patent/PE20020884A1/es not_active Application Discontinuation
2003
- 2003-07-14 ZA ZA200305412A patent/ZA200305412B/xx unknown
- 2003-07-15 BG BG107994A patent/BG66065B1/bg unknown
- 2003-07-22 US US10/623,775 patent/US6812253B2/en not_active Expired - Lifetime
- 2003-08-03 IL IL157208A patent/IL157208A/en not_active IP Right Cessation
- 2003-08-11 NO NO20033546A patent/NO333522B1/no not_active IP Right Cessation
2004
- 2004-08-18 US US10/920,395 patent/US7202278B2/en not_active Expired - Lifetime
2006
- 2006-12-06 CY CY20061101753T patent/CY1106278T1/el unknown

Also Published As

Publication number	Publication date
BG66065B1 (bg)	2011-01-31
PL363452A1 (en)	2004-11-15
US20050054729A1 (en)	2005-03-10
WO2002064146A1 (en)	2002-08-22
US7202278B2 (en)	2007-04-10
US20030022939A1 (en)	2003-01-30
NO20033546L (no)	2003-09-24
JP4317689B2 (ja)	2009-08-19
SI1361882T1 (sl)	2007-02-28
ZA200305412B (en)	2004-09-02
CA2437966C (en)	2011-06-14
JP2004518713A (ja)	2004-06-24
TWI241190B (en)	2005-10-11
BG107994A (bg)	2004-08-31
IL157208A (en)	2009-09-22
DE60215919D1 (de)	2006-12-21
CZ20032154A3 (cs)	2004-05-12
RU2308946C2 (ru)	2007-10-27
CN100553631C (zh)	2009-10-28
BR0207178A (pt)	2004-03-30
US20040019114A1 (en)	2004-01-29
CY1106278T1 (el)	2011-10-12
KR20030074809A (ko)	2003-09-19
EE200300368A (et)	2003-10-15
SK286513B6 (sk)	2008-12-05
US6617359B2 (en)	2003-09-09
KR101017531B1 (ko)	2011-02-28
PT1361882E (pt)	2007-01-31
NZ527469A (en)	2005-04-29
DE60215919T2 (de)	2007-05-31
NO20033546D0 (no)	2003-08-11
PE20020884A1 (es)	2002-11-25
CN1496264A (zh)	2004-05-12
DK1361882T3 (da)	2007-03-12
MXPA03006841A (es)	2003-11-13
NO333522B1 (no)	2013-07-01
RS51645B (sr)	2011-10-31
SK10112003A3 (sk)	2004-01-08
ATE344669T1 (de)	2006-11-15
HK1062140A1 (en)	2004-10-21
MY135778A (en)	2008-06-30
RU2003127750A (ru)	2005-03-10
EP1361882A1 (en)	2003-11-19
AU2002253009B2 (en)	2006-09-14
EE05302B1 (et)	2010-06-15
ES2274025T3 (es)	2007-05-16
HUP0302845A3 (en)	2005-11-28
CA2437966A1 (en)	2002-08-22
US6812253B2 (en)	2004-11-02
EP1361882B1 (en)	2006-11-08
HUP0302845A2 (hu)	2003-12-29
RS61703A (sr)	2006-12-15
HRP20030646A2 (en)	2005-06-30

Publication	Publication Date	Title
IL157208A0 (en)	2004-02-19	4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical
MXPA04009163A (es)	2004-12-07	Nuevos compuestos.
SE0001899D0 (sv)	2000-05-22	New compounds
CY1107850T1 (el)	2013-06-19	Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
SE0100569D0 (sv)	2001-02-20	New compounds
GB0105772D0 (en)	2001-04-25	Use
MXPA02007942A (es)	2004-09-10	Derivados de pirrolopirimidinona, procesos de preparacion y uso.
SE0101387D0 (sv)	2001-04-20	Novel compounds
MXPA04006051A (es)	2004-09-27	Bifenilmetil-tiazolidindionas, analogos y su uso como activadores de ppar-gamma.
UY27368A1 (es)	2003-01-31	Nuevos compuestos
ATE381537T1 (de)	2008-01-15	Formanilid-derivative als beta2-adrenorezeptor- agonisten
ECSP066314A (es)	2006-07-28	Derivados piridilo y su uso como agentes terapéuticos
TNSN06032A1 (en)	2007-10-03	Pyridazine derivatives and their use as therapeutic agents
TW200518753A (en)	2005-06-16	Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
BG106095A (bg)	2002-06-28	Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
GEP20053510B (en)	2005-05-10	Substituted Pyrrolopyridinone Derivatives Useful as Phosphodiesterase Inhibitors
BR0209283A (pt)	2004-07-13	Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
PL357132A1 (en)	2004-07-12	Stable, nasally, orally or sublingually applicable pharmaceutical preparation
SE0102440D0 (sv)	2001-07-05	New compound
SE0004462D0 (sv)	2000-12-04	Novel method and use
AR030945A1 (es)	2003-09-03	Amidas de acido fenilciclohexanocarboxilico sustituido y su uso
HRPK20040328B3 (en)	2006-02-28	Pharmaceutical composition comprising gamma-butyrobetaine
MY131159A (en)	2007-07-31	New pharmaceutical compositions containing epinastine and pseudoephedrine
UY27475A1 (es)	2003-06-30	Amidas de ácido piperazinciclohexanocarboxílico sustituidas y su utilización
AU2002211217A1 (en)	2002-04-29	Method of treating stroke